Clinical Trial Update: Aripiprazole Open-Label, Safety and Tolerability Study [Phase 3]

View source ↗

Summary

This is an open-label Phase 3 study of aripiprazole assessing safety and tolerability in schizophrenia and bipolar disorder; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia, Bipolar Disorder | Phase 3 | Status: COMPLETED | Results posted: 2012-08-31